Clinical Trials
136 trialsLIGHT-NING
Bristol-Myers Squibb
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
AstraZeneca
CASCADE
AstraZeneca
PASSAT
AstraZeneca
SCOOT
University of Oxford
CREATE
AstraZeneca
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
Pfizer
FOREFRONT
AstraZeneca
Tumor-informed MRD for Non-small Cell Lung Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
MYLUNG
US Oncology Research
OvAR-Y
Washington University School of Medicine
SURVIMON
N.N. Petrov National Medical Research Center of Oncology
ASCENT
University College, London
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases
Brigham and Women's Hospital
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
Pfizer
PLuS2
University of Florida
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
Regeneron Pharmaceuticals
Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases
Brigham and Women's Hospital
Using e-Nose Technology to Identify Early Lung Cancer
Memorial Sloan Kettering Cancer Center
Early Detection of Lung Cancer
Vanderbilt-Ingram Cancer Center
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
M.D. Anderson Cancer Center
TRACERx
University College, London
SHIELD
Guardant Health, Inc.
CYBRID-01
Elephas
ELEPHAS-02
Elephas
Multimodal CT-Based Risk Stratification for Postoperative Local Recurrence in NSCLC: A Multicenter Study
Jinling Hospital, China
Circulating Tumor Cells (CTC) in Lung Cancer
Indiana University
Real World Registry for Use of the Ion Endoluminal System
Intuitive Surgical
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
Wake Forest University Health Sciences
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
RATS_RYC
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
SWOG Cancer Research Network
ENTIRETY
Takeda
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
Hoffmann-La Roche
Reminder Messages for Lung Cancer Screening
M.D. Anderson Cancer Center
SORT
Washington University School of Medicine
Safety and Efficacy of Xalkori ROS1
Pfizer
Immune and Genomic Markers in ALK+ NSCLC
Massachusetts General Hospital
AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
Fudan University
PET-CT Predicting Lymph Nodes Metastasis
Fudan University
DELFI-L201
Delfi Diagnostics Inc.
NIS durvalumab
AstraZeneca
IPF-LC-IO
The First Affiliated Hospital with Nanjing Medical University
Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
Sun Yat-sen University
Palliative Thoracic ImmunoRT
University Health Network, Toronto
PET-Rad-NSCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations
AstraZeneca